Cerebras Systems has filed an updated IPO prospectus that targets a $3.5 billion raise at a $26.6 billion valuation, a significant reduction from the $40 billion figure the company had hinted at three days earlier. The AI chipmaker will sell 28 million shares at $115 to $125 each, with an underwriter option for an additional 4.2 million shares that could add roughly $525 million at the high end of the range.
Overview
The revised terms align the offering with Cerebras's February private valuation of $23 billion after its Series H round, rather than the more ambitious $40 billion mark. The company plans to list on the Nasdaq Global Select Market under the ticker CBRS, with Morgan Stanley, Citigroup, Barclays, and UBS Investment Bank as joint book-running managers. CEO Andrew Feldman, who is not selling shares in the IPO, will hold 10.3 million shares post-deal, worth as much as $1.28 billion at the high end.
Financial profile
Cerebras's most recent quarter showed revenue up roughly 76 percent year-on-year to $510 million, with $87.9 million in net income. The company's Master Relationship Agreement with OpenAI, signed in January, promises up to 750 megawatts of inference capacity through 2028, a contract Cerebras has previously valued at more than $20 billion over its term. That deal has anchored the IPO narrative more than any single demonstration of wafer-scale technology.
Why the valuation came down
There are three plausible readings of the shift from a possible $4 billion raise at $40 billion to a marketed $3.5 billion at roughly $26.6 billion. The first is execution: filing at a wider range and a more sober valuation reduces the risk of an undersubscribed book on launch day, and gives the deal room to price up if demand is strong. After two years in which AI hardware listings have priced below initial ranges as often as above, that discipline is sensible.
The second is market context. AI software multiples have been compressing through April, with Palantir down roughly 30 percent year-to-date and Citi cutting price targets across the AI-platform space. While Cerebras is hardware rather than software, hardware listings have not been immune to that broader recalibration.
The third is concentration risk. Public-market investors will have noted that OpenAI is the dominant customer in the deal. The economics, if OpenAI executes as planned, are formidable. If OpenAI's compute demand recalibrates, even modestly, Cerebras's near-term revenue trajectory recalibrates with it. That risk does not go away at $26.6 billion; it is,